Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5087508 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL967115 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL967130 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL19873253 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL1042158 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL19873263 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL19873261 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL4001962 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL22204611 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL635917 | 1.00 | DNM1 (0.94) | DNM1SLC22A1ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005876-A | Medical ultrasonic hydrogel and preparation method thereof | 华中科技大学同济医学院附属同济医院 | 2026-05-12 | — | — | CN | claimed |
| US-12589383-B2 | Spherical titanium silicalite molecular sieve catalyst and preparation method therefor | Shanghai HuaYi New Material Co., Ltd (CN) | 2026-03-31 | — | — | US | claimed |
| WO-2025094028-A1 | CROSSLINKING SYSTEM FOR FLUOROELASTOMERS | GUJARAT FLUOROCHEMICALS LIMITED (IN) | 2025-05-08 | — | — | WO | claimed |
| CN-119488885-A | Modified porous microsphere, preparation method thereof, separation device and application thereof | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-119488884-A | Modified porous microsphere, preparation method thereof, separation device and application thereof | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-118724992-A | Synthesis process of estrone | 秦皇岛紫竹药业有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-116354359-B | Pure silicon MFI structure molecular sieve and preparation method thereof | 中国石油天然气股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-117965021-A | Pure-color 3D printing nylon powder and preparation method thereof | 万华化学集团股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117918366-A | Pesticide preparation with high adhesiveness to plant leaves | 硅羿科技（上海）有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20240100512-A1 | Spherical Titanium Silicalite Molecular Sieve Catalyst and Preparation Method Therefor | Shanghai HuaYi New Material Co., Ltd (CN) | 2024-03-28 | — | — | US | claimed |
| EP-1311485-A1 | PROCESSES FOR PREPARING CILOSTAZOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-05-21 | — | — | EP | claimed |
| US-6515128-B2 | Dissolving 6-hydroxy-3,4-dihydroquinolinone and a base in water; dissolving a 1-cyclohexyl-5- (4-halobutyl)-tetrazole in water-immiscible solvent, mixing aqueous phase and organic phase in presence of phase transfer catalyst; recovering | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-02-04 | — | — | US | claimed |
| US-20020099213-A1 | Processes for preparing cilostazol | TEVA PHARMACEUTICALS USA, INC. | 2002-07-25 | — | — | US | claimed |
| WO-2002014283-A1 | PROCESSES FOR PREPARING CILOSTAZOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-02-21 | — | — | WO | claimed |
| US-6344563-B1 | SULFIDING, DEHYDROHALOGENATION, FORMATION OF BOND BETWEEN CARBON AND NITROGEN | NORRIS TIMOTHY (US) | 2002-02-05 | — | — | US | claimed |
| CN-1291609-A | Method of preparing 5-lipoxidase inhibitor possessing different heterocyclic ring system | PFIZER PROD INC (US) | 2001-04-18 | — | — | CN | claimed |
| EP-1081146-A1 | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| EP-1081144-A2 | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| CN-1286251-A | Method for preparing 5-lipooxygenase inhibitor having changeable heterocycle system | PFIZER PROD INC (US) | 2001-03-07 | — | — | CN | claimed |
| US-3966825-A | Process for preparing β-nitroethanethiol | SYNTEX (U.S.A.) INC. (US) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099213-A1 | Processes for preparing cilostazol | PDE3A, PDE12, PDE5A | DNM1 3161/4885SLC22A1 4650/4885ALDH1A1 2070/4885 |
| US-12589383-B2 | Spherical titanium silicalite molecular sieve catalyst and preparation method therefor | SOST, SSRP1, SEM1 | DNM1 1812/4885SLC22A1 4290/4885ALDH1A1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.